ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 2632

The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory

Joshua Liu1, Kathleen Teves2, Van La2, Arlene Bravo3, Sheila Lezcano4, Talha Khawar4, Ebrahim Sadeghi4, Cong-Bin Wang5, Karina Torralba6, Howard Yang5 and Vaneet K. Sandhu7, 1Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, 2Internal Medicine, University of California, Riverside, Riverside, CA, 3Internal Medicine, Loma Linda University, Loma Linda, CA, 4Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, 5Loma Linda University Medical Center, Loma Linda, CA, 6Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, 7Division of Rheumatology, Loma Linda University, Loma Linda, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: laboratory tests and registries, Lupus, SLE

Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in the Inland Empire, an under-recognized region of southern California inhabiting more than 3 million individuals where the percentage population living below the federal poverty line exceeds the general population in California. We report herein a preliminary analysis of baseline characteristics and clinical manifestations to establish a platform for future studies on regional disparities.

Methods: Subjects were enrolled into the SCOLR study from June 2016 to June 2017 using the Systemic Lupus International Collaborating Clinic (SLICC) classification criteria for SLE. Retrospective review of medical records as well as clinical visits yielded more than 80 variables including demographic and clinical data, disease activity, comorbidities, serologic identifiers for SLE, and treatment history. Data involving clinical manifestations including renal involvement were analyzed with descriptive statistics.

Results: Of the 147 subjects enrolled, the majority resided in the surrounding geographic areas of the participating institution (Loma Linda University Medical Center). Ninety-two percent (135) were women and 8% (12) were men (female:male ratio, 11) with a mean age of 42 years (range 19-85). Thirty-seven percent were White non-Hispanic, 37% White Hispanic, 10% Asian, and 16% Black. Positive antinuclear antibody was demonstrated in 90%, dsDNA antibody in 52%, and Smith antibody in 34% of subjects. Lupus nephritis was noted in 46 subjects, of whom greater than 50% were of Hispanic origin. SLEDAI score was also notably greater in the Hispanic population compared to other subsets.

Conclusion: Subjects with SLE residing in the Inland Empire demonstrate findings in line with other cohorts with greater disease activity and severity among non-White groups compared to Whites and Hispanic subjects specifically in our cohort appearing to be at greater risk of morbidity and mortality. Our preliminary data warrants further analysis of racial/ethnic subsets in serologies and disease manifestations.

Table 1. Baseline Characteristics

Current age, average (range)

42 (19-85)

Disease duration, average (range)

10.6 (1-46)

Female, n (%)

135 (92)

Race / Ethnicity (n)

White Hispanic

55

White non-Hispanic

55

Black

23

Asian/Pacific-Islander

14

Serologies (n, %)

Antinuclear Antibody

105/117 (90%)

dsDNA Antibody

66/128 (52%)

Smith Antibody

38/113 (34%)

Anti-Ro/SSA antibody

46/85 (54%)

Anti-La/SSB antibody

15/81 (19%)

Ribonucleoprotein antibody

40/90 (44%)

Lupus anticoagulant

21/84 (25%)

Beta-2gp IgM

6/ 73 (8%)

Beta-2gp IgG

7/ 62 (11%)

Cardiolipin IgM

19/93 (20%)

Cardiolipin IgG

11/72 (15%)

Clinical manifestations (%)

Mucocutaneous abnormalities

96/124 (77%)

Serositis

36/117 (31%)

Arthritis

94/123 (76%)

Hematologic abnormalities

45/117 (38%)

Lupus nephritis

46/147 (31%)

White non-Hispanic

6

White Hispanic

26

Asian

6

Black

8

Treatment history (current or prior)

Hydroxychloroquine

97%

Azathioprine

46%

Mycophenolate

42%

Cyclophosphamide

23%

Belimumab

22%

Prednisone

75%

SLEDAI score

0

10

1-5 (mild)

38

6-10 (moderate)

22

>10 (severe

10


Disclosure: J. Liu, None; K. Teves, None; V. La, None; A. Bravo, None; S. Lezcano, None; T. Khawar, None; E. Sadeghi, None; C. B. Wang, None; K. Torralba, None; H. Yang, None; V. K. Sandhu, None.

To cite this abstract in AMA style:

Liu J, Teves K, La V, Bravo A, Lezcano S, Khawar T, Sadeghi E, Wang CB, Torralba K, Yang H, Sandhu VK. The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-southern-california-lupus-registry-i-baseline-characteristics-of-patients-with-systemic-lupus-erythematosus-in-an-uncharted-territory/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-southern-california-lupus-registry-i-baseline-characteristics-of-patients-with-systemic-lupus-erythematosus-in-an-uncharted-territory/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology